Dormotech published a new case report evaluating the home-based detection of REM Sleep Without Atonia (RSWA) using the DormoVision X™ Type-2 Home PSG platform.
Published
Signal category
Research & Knowledge
Quote
“We evaluated the home-based detection of REM Sleep Without Atonia (RSWA)—a key diagnostic feature of REM Sleep Behavior Disorder (RBD) and a strong predictor of neurodegeneration—using the DormoVision X™ Type-2 Home PSG platform.”
— Dormotech team
Company
Dormotech
Every sleep study, one platform.
- Industry
- Medical Equipment Manufacturing
- Location
- Youngstown, US
- Company size
- 27 employees
Dormotech Medical Ltd. is a digital health company redefining the way sleep disorders are monitored and diagnosed. Our next-generation solution, DormoVision X™, is compact, multi-channel, reusable, and designed for patient-friendly self-setup at home. Built for both adult and pediatric use, it supports scalable remote diagnostics over multiple nights—making sleep studies more accessible, accurate, and efficient! Dormotech is driving a shift that meets today’s digital health standards, empowering providers and improving outcomes through real-time monitoring, clinical-grade data, and seamless patient experience.